Management of Toxicity and Side Effects of Systemic Therapy for Renal Cell Carcinoma
Standard approved systemic treatment options for the management of renal cancer have entirely transformed in the last 15 years and now comprise molecularly targeted therapies against the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR) as well as immun...
Saved in:
| Main Authors: | Kate Young, Andreas M. Schmitt, Deborah Mukherji, Lavinia Spain, Manuela Schmidinger, Lisa M. Pickering |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/download/224/160 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01) -
Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma
by: Naomi B. Haas, et al.
Published: (2022-11-01) -
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01) -
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis
by: Shuyun Wang, et al.
Published: (2024-10-01) -
Interdisciplinary approach to the management of patients with uterine cancer progression
by: K. Yu. Morkhov, et al.
Published: (2022-05-01)